EQT Chief Sees European PE Opportunity as Continent's Tech and Space Sectors Gain Momentum

The Quick Take

• EQT, Europe's largest private equity firm, sees significant investment opportunities in European biotech, aerospace, and technology sectors.
• EQT CEO Per Franzén told FAZ the firm actively collaborates with EU institutions, framing regulatory engagement as a competitive advantage rather than a burden.
• Europe's maturing startup ecosystem in deep tech, space, and life sciences is attracting institutional capital at scale for the first time in a decade.

EQT, Europe's largest private equity firm with over €230 billion in assets under management, is signaling a significant optimistic view on European investment opportunities. CEO Per Franzén told FAZ Finanzen that the firm sees compelling value in European biotech, aerospace/space technology, and broader technology sectors — arguing that something meaningful is happening across the continent's innovation ecosystem. EQT's perspective is significant as a bellwether: when Europe's largest PE house signals sector rotation into deep tech and life sciences, institutional capital typically follows, compressing valuations and accelerating deal activity in the targeted sectors.

The European PE market has historically struggled with the valuation gap between U.S. and European comparable companies, but the post-pandemic period has seen this discount narrow in several sectors. Life sciences companies in Germany, Sweden, and the UK have successfully commercialized biotech pipelines, while European space companies like OHB, Eutelsat, and Thales Alenia Space are capitalizing on the sovereign space race driven by both national security and commercial satellite demand. EQT's willingness to collaborate with EU institutions — rather than fighting regulatory frameworks — positions it favorably for deals in sectors where EU strategic autonomy investment programs provide co-investment or de-risking mechanisms.

Watch EQT's next fundraising cycle announcement, which will reveal the scale of capital being directed toward European opportunities and test LP appetite for European exposure. Monitor European biotech M&A activity, where EQT's deal announcements typically signal broader sector consolidation momentum. The macro variable determining European PE performance: ECB rate trajectory. A prolonged high-rate environment compresses PE exit multiples on leveraged buyouts, while a rate-cut cycle reopens IPO windows and M&A financing, improving the European PE return environment substantially.

Synthesized from 1 source.